TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A November 6, 2026, MedPage Today roundup highlights three developments: doctors caution that some menopausal hormone therapies carry a small breast cancer risk; ASCO says Medicare physician payments for oncology care are set to fall about 2% in 2027; and UCLA Health reports that routine breast imaging may not benefit women treated for ductal carcinoma in situ with double mastectomy. The reports do not establish that hormone therapy causes cancer in every patient or that imaging is unnecessary for every person after mastectomy.
A November 6, 2026, cancer news roundup reported that doctors caution against overlooking a small increase in breast cancer risk linked to certain hormone therapies, while the American Society of Clinical Oncology says oncologists treating Medicare patients face an approximately 2% payment cut in 2027. The roundup also cites UCLA Health reporting that routine mammograms or other breast imaging may not benefit some women who had a double mastectomy for ductal carcinoma in situ (DCIS).
The hormone-therapy item, attributed in the roundup to the New York Times, warns that some hormonal treatments for menopause symptoms are associated with a small increase in breast cancer risk. Separately, the Guardian reported that the U.S. Food and Drug Administration removed boxed warnings about breast cancer, cardiovascular disease and dementia from the labels of three estrogen patches. The roundup does not identify the patches or provide the evidence and regulatory explanation behind the label change, so it does not establish that the FDA action applies to all hormone therapies.
ASCO said oncologists treating people covered by Medicare will see an estimated roughly 2% cut under the 2027 Physician Fee Schedule from the Centers for Medicare & Medicaid Services. The association also said it is monitoring possible effects on cancer care delivery after heavy monsoon rains flooded and closed a facility in India that manufactures sterile injectable generic oncology medicines. The report does not quantify the facility’s output or describe any resulting shortages.
On post-mastectomy imaging, the roundup cites UCLA Health’s account that women who underwent double mastectomy to treat DCIS may not benefit from routine mammograms or other breast imaging. This is a qualified finding about a particular group, not a recommendation that every patient stop follow-up. The source summary does not provide the study design, patient numbers or individual circumstances underlying that conclusion.
Implications for Treatment and Access
These developments concern three decisions with direct consequences for patients and care teams: weighing menopause symptom relief against possible risk, sustaining cancer services under Medicare payment rules, and choosing follow-up after surgery. The reports point to issues that warrant discussion, but they do not give enough detail to replace individualized clinical advice or determine how any single patient should be treated.
The projected payment reduction matters because oncology practices rely on Medicare reimbursement to deliver care to older adults and other eligible patients. ASCO has raised the possibility of effects on care delivery, but the roundup gives no estimate of how practices might respond or whether patients will see changes. The India facility closure could also matter to supply of generic injectable medicines, although no shortages or disruptions are confirmed in the supplied report.
For patients, the distinction between a population-level finding and a personal recommendation is important. A risk described as small is not the same as no risk, and a finding about routine imaging after a specific operation does not settle follow-up for people with different diagnoses or surgeries.
Products Worth Considering
Therabody Theragun Relief Massage Gun, 3-Speed, Black
Therabody SleepMask with Vibration
Garmin Forerunner 165 GPS Running Smartwatch, 43 mm, Black
As an affiliate, we earn on qualifying purchases.
Three Separate Cancer Care Updates
The items appear in a daily roundup of cancer-related news rather than as one connected study or policy announcement. The hormone-therapy and imaging items concern breast cancer risk and follow-up, while the payment item concerns the federal schedule for physician reimbursement. Their appearance together does not imply that one development caused or explains another.
DCIS is named in the report as the condition for which some women underwent double mastectomy. The imaging finding is framed around that group, and the source offers no basis for extending it to all breast cancer survivors or all people who have had a mastectomy. Similarly, the reported FDA label change concerns three estrogen patches, not every product used for menopause symptoms.
ASCO’s payment figure refers specifically to its estimate for oncologists treating Medicare patients under the 2027 Physician Fee Schedule. The roundup does not include the underlying fee schedule calculation or details on implementation. Its mention of the flooded Indian manufacturing facility is a separate supply-chain concern that ASCO said it was monitoring.
“Do not overlook the small increase in breast cancer risk associated with certain hormonal therapies for treating menopause symptoms.”
— Doctors, as summarized in the New York Times item cited by MedPage Today
Evidence and Patient-Level Effects
The available summary does not name the hormone therapies associated with increased risk, quantify that risk, or explain which patients may be most affected. It also does not identify the three estrogen patches whose boxed warnings the FDA removed or explain the evidence used for that decision. The label change should not be read as proof that all hormone therapy is risk-free.
Details behind the post-mastectomy imaging finding are also absent: the report does not provide the number of patients studied, follow-up period, or how the finding varies by individual risk. It remains unclear what specific follow-up schedules clinicians should recommend. For the Medicare change, the final payment details and any effects on access or practice operations are not supplied. The roundup reports a facility closure in India but confirms no medicine shortages, shipping delays or patient impact.
Clinical Guidance and Payment Details
Patients considering or using menopause hormone therapy can discuss the specific product, potential benefits and risks, and personal medical history with a clinician. People who have had a double mastectomy for DCIS should ask their care team what follow-up is appropriate for their circumstances rather than changing imaging plans based only on a brief roundup item.
ASCO said it is monitoring possible effects of the Medicare payment schedule and the Indian facility closure on cancer care. The supplied report does not give a further timeline, a response from CMS, or updates on the facility’s reopening or medicine supply. More detailed policy information and clinical evidence would be needed to assess the practical effects of these developments.
Key Questions
Does the report say all menopause hormone therapy increases breast cancer risk?
No. It refers to a small increase associated with certain hormonal therapies. The roundup does not name all affected treatments or provide individual risk estimates.
Did the FDA remove boxed warnings from every hormone therapy?
No. The roundup says the FDA removed specified boxed warnings from the labels of three estrogen patches. It does not say the action covers all hormone products.
Who may be affected by the reported 2027 oncology pay cut?
ASCO said the roughly 2% cut applies to oncologists treating Medicare patients under the 2027 Physician Fee Schedule. The report does not describe how individual practices or patients will be affected.
Should everyone stop mammograms after a double mastectomy?
No such broad recommendation is established by the roundup. The cited report says routine imaging may not benefit some women treated for DCIS with double mastectomy; patients should confirm follow-up plans with their own care team.
Were cancer drug shortages confirmed after the flooding in India?
No. ASCO said it was monitoring the possible effect of a flooded facility that manufactures sterile injectable generic oncology medicines. The roundup does not report confirmed shortages or patient-care disruptions.
Source: medpagetoday.com
